The estimated Net Worth of Jean Pierre Sommadossi is at least $22.6 million dollars as of 5 June 2024. Dr Sommadossi owns over 1,006 units of Atea Pharmaceuticals stock worth over $21,741,058 and over the last 6 years he sold AVIR stock worth over $4,024. In addition, he makes $902,987 as Founder, Chairman et CEO & Pres at Atea Pharmaceuticals.
Dr has made over 2 trades of the Atea Pharmaceuticals stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 1,006 units of AVIR stock worth $4,024 on 5 June 2024.
The largest trade he's ever made was exercising 173,467 units of Atea Pharmaceuticals stock on 31 January 2024 worth over $636,624. On average, Dr trades about 19,386 units every 14 days since 2018. As of 5 June 2024 he still owns at least 5,923,994 units of Atea Pharmaceuticals stock.
You can see the complete history of Dr Sommadossi stock trades at the bottom of the page.
Dr. Jean-Pierre Sommadossi Ph.D. is the Founder, Chairman, CEO & Pres at Atea Pharmaceuticals.
As the Founder, Chairman et CEO & Pres of Atea Pharmaceuticals, the total compensation of Dr D at Atea Pharmaceuticals is $902,987. There are no executives at Atea Pharmaceuticals getting paid more.
Dr D is 65, he's been the Founder, Chairman et CEO & Pres of Atea Pharmaceuticals since . There are no older and 9 younger executives at Atea Pharmaceuticals.
Jean's mailing address filed with the SEC is 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110.
Over the last 4 years, insiders at Atea Pharmaceuticals have traded over $279,832 worth of Atea Pharmaceuticals stock and bought 553,666 units worth $13,102,824 . The most active insiders traders include Andrew A. F. Hack, Franklin M Berger et Springs Capital Management .... On average, Atea Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $229,012. The most recent stock trade was executed by Bruce Polsky on 20 June 2024, trading 17,544 units of AVIR stock currently worth $61,229.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals executives and other stock owners filed with the SEC include: